Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Chardan Capital in a report released on Wednesday,Benzinga reports. They presently have a $425.00 price objective on the biopharmaceutical company’s stock. Chardan Capital’s price target indicates a potential upside of 30.05% from the stock’s previous close.
Several other research firms have also issued reports on ALNY. Wells Fargo & Company reduced their price target on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a research report on Tuesday, January 20th. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research report on Friday, January 30th. Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Truist Financial decreased their target price on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Finally, Stifel Nicolaus upped their price target on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $468.84.
Check Out Our Latest Research Report on ALNY
Alnylam Pharmaceuticals Trading Up 6.1%
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same period last year, the business posted ($0.65) earnings per share. The firm’s quarterly revenue was up 84.9% compared to the same quarter last year. As a group, analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.
Insider Activity at Alnylam Pharmaceuticals
In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 2,780 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the completion of the transaction, the executive vice president directly owned 57,465 shares in the company, valued at approximately $20,852,324.55. This represents a 4.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Pushkal Garg sold 2,242 shares of the firm’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the sale, the executive vice president directly owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. This represents a 8.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 53,923 shares of company stock valued at $18,072,087 in the last 90 days. 1.20% of the stock is owned by company insiders.
Hedge Funds Weigh In On Alnylam Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the stock. Root Financial Partners LLC bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $25,000. MV Capital Management Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $25,000. Salomon & Ludwin LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $27,000. HM Payson & Co. bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $27,000. Finally, Golden State Wealth Management LLC grew its stake in Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the period. 92.97% of the stock is owned by institutional investors.
Key Headlines Impacting Alnylam Pharmaceuticals
Here are the key news stories impacting Alnylam Pharmaceuticals this week:
- Positive Sentiment: Needham (Joseph Stringer) reiterated a Buy and kept a $510 price target, citing an underpenetrated TTR market and strong commercial execution that support upside for Alnylam. Alnylam Pharmaceuticals: Underpenetrated TTR Market and Strong Commercial Execution Support Buy Rating
- Positive Sentiment: Bank of America (Tazeen Ahmad) maintained a Buy rating, highlighting durable ATTR growth and momentum for Amvuttra as drivers of near‑term commercial upside. Alnylam Pharmaceuticals: Durable ATTR Growth and Amvuttra Momentum Support Buy Rating and Upside Potential
- Positive Sentiment: Alnylam announced a strategic collaboration with Viz.ai and support for the American Heart Association to accelerate earlier identification and care coordination for ATTR‑CM — a move that could expand diagnosis rates and address the underpenetrated market the analysts reference. Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
- Positive Sentiment: Coverage notes Alnylam tying AI partnerships to the ATTR‑CM growth and access story — reinforcing the message that diagnostic and digital-health initiatives could drive higher patient identification and ultimately treatment uptake. Alnylam Ties AI Partnerships To ATTR CM Growth And Access Story
- Neutral Sentiment: Transcript coverage (investor/earnings-era discussion) outlines Alnylam’s strategy to transform ATTR care and expand the TTR franchise — useful context but no new clinical or financial data that would immediately move the stock. Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR Franchise Transcript
- Neutral Sentiment: Multiple short‑interest notices in the feed show “significant increase” but report zero shares/NaN values — the data appears erroneous or unreliably reported and shouldn’t be interpreted as meaningful evidence of rising short pressure today.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
See Also
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
